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Rapid Emergence 
of Oseltamivir 
Resistance
To the Editor: The inﬂ  uenza 
A pandemic (H1N1) 2009 virus has 
spread globally since it ﬁ  rst appeared 
in Mexico in April 2009. This third 
inﬂ   uenza pandemic since the Span-
ish inﬂ   uenza pandemic of 1918 (1) 
has caused at least 400,000 infections 
within 6 months; estimated mortality 
rate is 1.2% (2). Emergence of osel-
tamivir resistance in the pandemic 
(H1N1) 2009 virus is a rising chal-
lenge to global control of the pan-
demic. So far, 39 oseltamivir-resistant 
pandemic (H1N1) 2009 viruses have 
been reported worldwide (3). Among 
the 32 resistant strains reported in Oc-
tober 2009, a total of 13 (41%) were 
associated with postexposure chemo-
prophylaxis and 16 (50%) were from 
samples of patients receiving oselta-
mivir (3). We report rapid emergence 
of resistance (H275Y mutation) in a 
patient, 4 days after early treatment 
with standard doses of oseltamivir for 
pandemic (H1N1) 2009 pneumonia.
On September 1, 2009, a 20-year-
old man with mental retardation con-
sulted the emergency department of 
Kaohsiung Veterans General Hospital 
after 1 day of fever, sore throat, and 
nonproductive cough. A rapid diag-
nostic antigen test (Quick Vue Inﬂ  uen-
za test; Quidel, San Diego, CA, USA) 
showed the man to be positive for 
inﬂ  uenza A. He was hospitalized for 
bilateral pneumonitis and treated with 
oseltamivir (75 mg 2×/day for 5 days), 
ampicillin/sulbactam, and erythromy-
cin. However, a progressive increase 
in bilateral perihilar interstitial in-
ﬁ  ltration developed on the third day, 
accompanied by increasing dyspnea. 
Inﬂ  uenza A pandemic (H1N1) 2009 vi-
rus was isolated from the patient’s na-
sopharyngeal secretions on days 1 and 
4 by using MDCK cells. After DNA 
sequence analysis of the neuramini-
dase gene, the mutation of H275Y was 
not found in the ﬁ  rst isolate, but se-
quence analysis of the second isolate 
detected mixed populations (C/T) in 
the 823-nt position of the neuramini-
dase gene. Only a single pattern (T) 
was found from the cultured viruses, 
indicating a mixed quasispecies of 
oseltamivir-resistant and -susceptible 
viruses emerging after 4 days of os-
eltamivir treatment. The oseltamivir-
resistant viruses become dominant in 
the cell culture–propagated viruses. 
Chan et al. reported a similar case in 
which the original clinical specimens 
contained a mixed population of vari-
ants, and oseltamivir-resistant viruses 
become dominant after the passage in 
MDCK cells (4).
On his 9th day in the hospital, the 
patient was intubated because of acute 
respiratory distress syndrome (Figure) 
and given levoﬂ  oxacin. Urine samples 
were negative for Pneumococcus and 
Legionella spp. antigens. The patient 
improved and was extubated on hos-
pital day 16.
Paired serologic test results were 
negative for Mycoplasma pneumoniae 
and Legionella spp. antibody; howev-
er, immunoglobulin G for Chlamydia 
pneumoniae increased 4-fold. By 37 
days after illness onset, clinical signs 
and symptoms resolved and bilateral 
lineoreticular inﬁ  ltration was reduced.
On August 8, 2009, Taiwan had 
the most devastating typhoon (Ty-
phoon Morakot) in 50 years. The 
patient reported here had stayed in a 
typhoon evacuation camp for 1 week 
before his inﬂ  uenza signs and symp-
toms developed. Although 4 sporadic 
cases of pandemic (H1N1) 2009 in-
fections were reported from the same 
camp, none of the isolated viruses 
harbored the H275Y mutation in the 
neuraminidase gene. No evidence of 
virus transmission was found among 
healthcare personnel, family members, 
and camp members who had been in 
close contact with the patient.
Oseltamivir has been recommend-
ed by the US Centers for Disease Con-
trol and Prevention for the treatment of 
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infection caused by pandemic (H1N1) 
2009 virus (5). The ﬁ  rst 2 cases of osel-
tamivir resistance of pandemic H1N1 
(2009) virus were reported in August 
2009 (6). For these cases, oseltamivir-
resistant virus was isolated on days 11 
and 23 after the initial isolation of os-
eltamivir-susceptible viruses, for each 
patient, respectively. In contrast, in the 
case reported here, resistance to osel-
tamivir developed rapidly, after only 4 
days of treatment.
In severe cases of pandemic 
(H1N1) 2009 infections, mortality 
rates are highest for patients who are 
pregnant, <2 years of age, or obese, 
or who have chronic lung disease (7). 
The patient reported here was previ-
ously healthy except for mental retar-
dation; his body mass index was 23.9 
kg/m2. Progression of pneumonia to 
acute respiratory distress syndrome 
occurred despite early initiation of the 
standard dose of oseltamivir, within 
48 hours after illness onset and ini-
tial susceptibility of the virus. Clini-
cal deterioration might have resulted 
from the rapid emergence of an osel-
tamivir-resistant pandemic (H1N1) 
2009 virus with a H275Y mutation, 
which is known to confer a high level 
of oseltamivir resistance while retain-
ing zanamivir susceptibility (8), or it 
might have resulted from co-infection 
with C. pneumoniae. A 4-month study 
found concurrent bacterial infections 
in 29% of fatal cases of pandemic 
(H1N1) 2009 virus (9).
Oseltamivir resistance can emerge 
rapidly during treatment of pandemic 
(H1N1) virus infection. Healthcare 
providers should be aware that resis-
tance may emerge in otherwise appar-
ently healthy persons as early as day 
4 of treatment with standard doses of 
oseltamivir.
Cheng Len Sy, 
Susan Shin-Jung Lee, 
Ming-Tsan Liu, Hung-Ching Tsai, 
and Yao-Shen Chen
Author afﬁ   liations: Kaohsiung Veterans 
General Hospital, Kaohsiung, Taiwan (C.L. 
Sy, S.S.-J. Lee, H.-C. Tsai, Y.-S. Chen); Na-
tional Yang-Ming University, Taipei, Taiwan 
(S.S.-J. Lee, H.-C. Tsai, Y.-S. Chen); and 
Centers for Disease Control, Taipei (M.-T. 
Liu)
DOI: 10.3201/eid1604.091706
References
  1.   Nicholls  H.  Pandemic  inﬂ  uenza: the in-
side story. PLOS Biology. 2006;4:156–60. 
Epub 2006 Feb 14. DOI: 10.1371/journal.
pbio.0040156
  2.   World  Health  Organization.  Pan-
demic (H1N1) 2009: update 70 [cited 
2009 Oct 22]. http://www.who.int/csr/
don/2009_10_16/en/index.html
  3.   World Health Organization. Oseltamivir-
resistant pandemic (H1N1) 2009 inﬂ  uenza 
virus, October 2009. Wkly Epidemiol 
Rec. 2009;84:453–9.
  4.   Chen H, Cheung CL, Tai H, Zhao P, Chan 
JFW, Cheng VCC, et al. Oseltamivir-
resistant inﬂ  uenza  A  pandemic  (H1N1)
2009 virus, Hong Kong, China. Emerg In-
fect Dis. 2009;15:1970–2.
  5.   Centers for Disease Control and Preven-
tion. Updated interim recommendations 
for the use of antiviral medications in the 
treatment and prevention of inﬂ  uenza for 
the 2009–2010 season [cited 2009 Oct 
22]. http://www.cdc.gov/h1n1ﬂ  u/recom-
mendations.htm
  6.   Centers for Disease Control and Preven-
tion (CDC). Oseltamivir-resistant novel 
inﬂ   uenza A (H1N1) virus infection in 
two immunosuppressed patients—Seattle, 
Washington, 2009. MMWR Morb Mortal 
Wkly Rep. 2009;58:893–6.
  7.   World  Health  Organization.  Clinical 
features of severe cases of pandemic in-
ﬂ  uenza [cited 2009 Oct 22]. http://www.
who.int/csr/disease/swineﬂ  u/notes/h1n1_
clinical_features_20091016/en/
  8.   Escuret  V,  Frobert  E,  Bouscambert-Du-
champ M, Sabatier M, Grog I, Valette 
M, et al. Detection of human inﬂ  uenza A 
(H1N1) and B strains with reduced sensi-
tivity to neuraminidase inhibitors. J Clin 
Virol. 2008;41:25–8. DOI: 10.1016/j.
jcv.2007.10.019
724  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 4, April 2010
Figure. Radiograph (anteroposterior view) of patient with acute respiratory distress 
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  9.   Centers for Disease Control and Preven-
tion. Bacterial coinfections in lung tis-
sue specimens from fatal cases of 2009 
pandemic inﬂ  uenza  A  (H1N1)—United 
States, May–August 2009. MMWR Morb 
Mortal Wkly Rep. 2009;58:1071–4.
Address for correspondence: Yao-Shen 
Chen, Kaohsiung Veterans General Hospital, 
Infectious Diseases, No. 386 Ta-chung 1st Rd, 
Zuo-ying District, Kaohsiung 813, Taiwan; 
email: yschen@vghks.gov.tw
Dual Seasonal 
Patterns for 
Inﬂ  uenza, China
To the Editor: Since 2000, the 
People’s Republic of China has had 
a nationwide surveillance network 
for inﬂ  uenza, which as of 2005 has 
been reported on the Chinese Center 
for Disease Control and Prevention 
website (www.cnic.org.cn/ch/). This 
surveillance has shown a remarkable 
dual pattern of seasonal inﬂ  uenza on 
mainland China. Whereas a regular 
winter pattern is noted for northern 
China (similar to that in most parts of 
the Northern Hemisphere), the pattern 
in southern China differs. In southern 
China, inﬂ  uenza is prevalent through-
out the year; it has a clear peak in the 
summer and a less pronounced peak in 
the winter. Because this dual seasonal 
pattern of inﬂ  uenza has not been re-
ported outside China and is relevant to 
pandemic (H1N1) 2009, we describe 
surveillance data for rates of consulta-
tion for inﬂ  uenza-like illness (ILI) and 
inﬂ  uenza subtypes in patients with ILI. 
We emphasize the spread of inﬂ  uenza 
from southern to northern China.
Before it was extended in June 
2009, the National Inﬂ  uenza Surveil-
lance Network had been composed of 
63 inﬂ  uenza laboratories and 197 sen-
tinel hospitals across 31 provinces of 
mainland China. In 13 of 16 northern 
provinces, surveillance began from the 
week including October 1 and ended 
in the week including March 31 of the 
following year. In the 3 northern pro-
vincial areas of Liaoning, Tianjin, and 
Gansu and in all southern provinces, 
surveillance was conducted through-
out the year. Data consisted of infor-
mation about ILI cases and virus sub-
types. The sentinel hospitals deﬁ  ned 
ILI cases according to World Health 
Organization criteria: sudden onset 
of fever >38°C, cough or sore throat, 
and absence of other diagnoses (1). 
The number of ILI cases and the total 
number of outpatients at the sites (ILI 
consultation rate) were recorded each 
day and reported to the National Inﬂ  u-
enza Surveillance Information System 
each week.
Sentinel hospitals were required 
to collect 5–15 nasopharyngeal swabs 
each week from ILI patients who had 
not taken antiviral drugs and who 
had fever (>38°C) for no longer than 
3 days. The swabs were sent to the 
corresponding inﬂ  uenza  laboratories 
for virus isolation and identiﬁ  cation; 
results were reported to the National 
Inﬂ   uenza Surveillance Information 
System within 24 hours.
From the National Inﬂ  uenza Sur-
veillance Network, a database of sur-
veillance information from April 2006 
to March 2009 was established. For 
inﬂ  uenza surveillance purposes, main-
land China was divided into northern 
and southern parts, basically follow-
ing the Qinling Mountain range in the 
west and the Huai River in the east. 
The prominent inﬂ  uenza peaks in the 
winter in the north and summer in the 
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Figure. Epidemic patterns, by month, from the surveillance data of the inﬂ  uenza-like illness 
(ILI) consulting rate and inﬂ  uenza subtypes in ILI patients in mainland China, per month, 
April 2006–March 2009. A) ILI percentages for northern (dashed lines) and southern (solid 
lines) mainland China, by age group. B) Average temperature and relative humidity. A color 
version of this ﬁ  gure is available online (www.cdc.gov/EID/content/16/4/725-F.htm).